CD274 and urinary bladder carcinoma: Currently, there are three PD-L1 inhibitors and two PD-1 inhibitors approved by the Food and Drug Administration for the treatment of bladder cancer (Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, and Ipilimumab).